News
Economic Costs and Concomitant FVIII Consumption in Hemophilia Patients Treated with Emicizumab in the 1st Year − A US Experience
The authors of a recent study, summarizing real-world experience from the US, focused on the concomitant consumption of FVIII (Factor VIII) concentrates during emicizumab prophylaxis and the financial costs in the first year after starting emicizumab treatment.
Minimally Invasive Treatment of Pilonidal Sinus: Laser and Negative Pressure Therapy as a Gentle and Effective Modality
The increasing incidence of pilonidal sinus contributes to the development of new treatment…
Reduction of Enthesitis in Patients with Psoriatic Arthritis Taking Tofacitinib
Inflammation in the area where a tendon, ligament, or joint capsule attaches to the bone occurs in…
How do body weight and metabolic parameters change in patients first hospitalized for psychosis?
The most common cause of death in patients with schizophrenia is cardiovascular disease, which is…
Prof. Hana Rosolová: According to recent studies, caution is needed with beta-blockers only in severe cases of asthma and COPD
Beta-blockers (BB) are among the most widely used drug groups in cardiology. While their position…
Reduction of Inflammation in Vertebral Bodies and Posterolateral Structures of the Spine in Patients with Ankylosing Spondylitis Treated with Tofacitinib
A post hoc analysis of a phase II study with tofacitinib in patients with active ankylosing…
How Do Patients Themselves Perceive Today's Treatment Options for ITP and What Are Their Biggest Fears?
What is the perception and view of the treatment options for immune thrombocytopenia (ITP) from the…
Romiplostim brings benefit also to patients with ITP lasting less than 1 year
What is the role of second-line therapy, in this case romiplostim, in the management of adult ITP…
Stabilization of Transthyretin and Long-term Survival of Patients with Cardiac Amyloidosis
Tafamidis is used in the therapy of transthyretin amyloid cardiomyopathy (ATTR-CM), which has…
HVD 2023: Cervical Cancer May Be the First Eliminated Malignancy. What Paths Will Lead to This Goal in the Czech Republic?
Cervical cancer is the 3rd most common cancer among women aged 15–44. Annually, it is diagnosed in…